{"id":"W2607270289","doi":"10.1007/s00280-017-3287-8","title":"Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study","year":2017,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"Amgen","keywords":"Carfilzomib; Medicine; Multiple myeloma; Pharmacokinetics; End stage renal disease; Stage (stratigraphy); Oncology; Disease; Internal medicine; Intensive care medicine; Proteasome inhibitor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008984379,0.0007832686,0.001873287,0.000211146,0.0003274822,0.0006098363,0.0004268647,0.0008268093,0.0008962614],"category_scores_gemma":[0.001081838,0.0004350415,0.000798232,0.0002588725,0.0006308688,0.0006066045,0.0002105002,0.002061246,0.0003653787],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005849294,"about_ca_system_score_gemma":0.0007446344,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004600821,"about_ca_topic_score_gemma":0.0007975883,"domain_scores_codex":[0.9996146,0.0001580811,0.00002138736,0.00006792391,0.00007220705,0.00006578691],"domain_scores_gemma":[0.9993002,0.0001096814,0.0001626125,0.0000581086,0.00003469592,0.000334725],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5051801,0.08089615,0.09276111,0.0007033854,0.001643962,0.001608207,0.001213142,0.004258674,0.1776569,0.0002150048,0.003089475,0.1307739],"study_design_scores_gemma":[0.1433343,0.6500889,0.1872023,0.00003199051,0.0006796113,0.001879814,0.000141778,0.003889193,0.008891595,0.0001567076,0.003630799,0.00007296114],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9986958,0.0004715707,0.0001927123,0.00009047658,0.00001530103,0.0001598305,0.0001281397,0.00002766454,0.000218456],"genre_scores_gemma":[0.9980204,0.0003083276,0.0004543225,0.0002415088,0.00006321584,0.0001939688,0.0003563388,0.000007828348,0.0003540111],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001873287,"threshold_uncertainty_score":0.004751444,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05407738287008189,"score_gpt":0.3948468544672407,"score_spread":0.3407694715971588,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}